About Dova Pharmaceuticals
Dova Pharmaceuticals is a company based in Durham (United States) founded in 2016 was acquired by Swedish Orphan Biovitrum in September 2019.. Dova Pharmaceuticals has raised $10 million across 2 funding rounds from investors including Swedish Orphan Biovitrum and Perceptive Advisors. Dova Pharmaceuticals operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
- Headquarter Durham, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
Swedish Orphan Biovitrum
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Swedish Orphan Biovitrum
(Sep 30, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Dova Pharmaceuticals
Dova Pharmaceuticals has successfully raised a total of $10M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(23 Sep 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2017 | Amount | Post-IPO - Dova Pharmaceuticals | Valuation |
investors |
|
| Sep, 2016 | Amount | Series A - Dova Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dova Pharmaceuticals
Dova Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Swedish Orphan Biovitrum and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dova Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dova Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dova Pharmaceuticals Comparisons
Competitors of Dova Pharmaceuticals
Dova Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for sickle cell disease treatment.
|
|
| domain | founded_year | HQ Location |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| domain | founded_year | HQ Location |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| domain | founded_year | HQ Location |
Therapies for sickle cell disease and diabetic nephropathy are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dova Pharmaceuticals
Frequently Asked Questions about Dova Pharmaceuticals
When was Dova Pharmaceuticals founded?
Dova Pharmaceuticals was founded in 2016.
Where is Dova Pharmaceuticals located?
Dova Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is Dova Pharmaceuticals a funded company?
Dova Pharmaceuticals is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Sep 23, 2016.
What does Dova Pharmaceuticals do?
Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, United States. Operations focus on the pharmaceutical sector, specifically the acquisition, development, and commercialization of therapies for rare diseases. The lead product candidate, avatrombopag, an oral thrombopoietin receptor agonist, has completed Phase 3 trials for thrombocytopenia associated with chronic liver disease. An NDA filing is planned for the third quarter of 2017, with further indications under exploration.
Who are the top competitors of Dova Pharmaceuticals?
Dova Pharmaceuticals's top competitors include GBT, Editas Medicine and Kedrion.
Who are Dova Pharmaceuticals's investors?
Dova Pharmaceuticals has 2 investors. Key investors include Swedish Orphan Biovitrum, and Perceptive Advisors.